Characterization and outcomes in patients with mogamulizumab-associated skin reactions in the MAVORIC trial
Eur J Cancer
.
2021 Oct:156 Suppl 1:S46.
doi: 10.1016/S0959-8049(21)00712-7.
Authors
Amy C M Musiek
1
,
Sean Whittaker
2
,
Steven M Horowitz
3
,
Martine Bagot
4
,
Auris Huen
5
,
David C Fisher
6
,
Paul Haun
7
,
Maarten H Vermeer
8
,
Takahiro Ito
9
,
Karen Dwyer
9
,
Fiona Herr
10
,
Youn H Kim
11
Affiliations
1
Washington University, St. Louis, MO, United States.
2
King's College London, Strand, London, United Kingdom.
3
Memorial Sloan-Kettering Cancer Center, New York, NY, United States.
4
Hôpital Saint Louis, APHP, Inserm U976, Université de Paris, Paris, France.
5
MD Anderson Cancer Center, Houston, TX, United States.
6
Dana-Farber Cancer Institute, Boston, MA, United States.
7
University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, United States.
8
Leiden University Medical Center, Leiden, Netherlands.
9
Kyowa Kirin Pharmaceutical Development, Inc., Princeton, NJ, United States.
10
Kyowa Kirin, Inc., Bedminster, NJ, United States.
11
Stanford University, Stanford, CA, United States.
PMID:
34649656
DOI:
10.1016/S0959-8049(21)00712-7
No abstract available
Keywords:
CTCL; MAVORIC; Sézary syndrome; drug rash; mogamulizumab; mycosis fungoides.